Kenneth P. Olive, et.al., Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome., Cell, 2004, 119

http://rdf.ncbi.nlm.nih.gov/pubmed/15607980

Kenneth P. Olive, et.al., Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome., Cell, 2004, 119

pubmed

allele

http://purl.org/net/cito/citesAsAuthority

• Trp53<tm3Tyj>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3039265
• Trp53<tm2.1Tyj>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3039264
• Trp53<tm3.1Tyj>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3039266
• Trp53<tm2Tyj>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3039263

class

http://purl.org/net/cito/citesAsAuthority

• Trp53<tm3Tyj>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3039265
• Trp53<tm2.1Tyj>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3039264
• Trp53<tm3.1Tyj>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3039266
• Trp53<tm2Tyj>
  http://metadb.riken.jp/db/mgi_rdf/MGI:3039263

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• increased T cell derived lymphoma incidence_Trp53<tm1Tyj>/Trp53<tm1Tyj>
  http://metadb.riken.jp/0002024I129S2SvPasTrp53tm1TyjTrp53tm1TyjTrp53tm1Tyj
• premature death_Trp53<tm2.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0002083I129S4SvJaeTrp53tm21TyjTrp53Trp53tm21TyjTrp53
• increased carcinoma incidence_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0002038I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• prenatal lethality, incomplete penetrance_Trp53<tm1Tyj>/Trp53<tm1Tyj>
  http://metadb.riken.jp/0011101I129S2SvPasTrp53tm1TyjTrp53tm1TyjTrp53tm1Tyj
• increased B cell derived lymphoma incidence_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0002023I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• increased tumor incidence_Trp53<tm1Tyj>/Trp53<tm2.1Tyj>
  http://metadb.riken.jp/0002020I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm21TyjTrp53tm21TyjTrp53tm1Tyj
• increased hemangiosarcoma incidence_Trp53<tm1Tyj>/Trp53<tm2.1Tyj>
  http://metadb.riken.jp/0003667I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm21TyjTrp53tm21TyjTrp53tm1Tyj
• increased tumor incidence_Trp53<tm1Tyj>/Trp53<tm3.1Tyj>
  http://metadb.riken.jp/0002020I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm31TyjTrp53tm31TyjTrp53tm1Tyj
• increased carcinoma incidence_Trp53<tm1Tyj>/Trp53<+>
  http://metadb.riken.jp/0002038I129S2SvPasTrp53tm1TyjTrp53Trp53Trp53tm1Tyj
• premature death_Trp53<tm1Tyj>/Trp53<tm3.1Tyj>
  http://metadb.riken.jp/0002083I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm31TyjTrp53tm31TyjTrp53tm1Tyj
• increased T cell derived lymphoma incidence_Trp53<tm1Tyj>/Trp53<tm2.1Tyj>
  http://metadb.riken.jp/0002024I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm21TyjTrp53tm21TyjTrp53tm1Tyj
• increased cell proliferation_Trp53<tm2.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0000351I129S4SvJaeTrp53tm21TyjTrp53Trp53tm21TyjTrp53
• decreased cellular sensitivity to gamma-irradiation_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0003207I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• prenatal lethality, incomplete penetrance_Trp53<tm1Tyj>/Trp53<tm3.1Tyj>
  http://metadb.riken.jp/0011101I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm31TyjTrp53tm31TyjTrp53tm1Tyj
• increased fibroblast proliferation_Trp53<tm1Tyj>/Trp53<+>
  http://metadb.riken.jp/0011703I129S2SvPasTrp53tm1TyjTrp53Trp53Trp53tm1Tyj
• increased lung adenocarcinoma incidence_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0002027I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• premature death_Trp53<tm1Tyj>/Trp53<tm2.1Tyj>
  http://metadb.riken.jp/0002083I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm21TyjTrp53tm21TyjTrp53tm1Tyj
• prenatal lethality, incomplete penetrance_Trp53<tm1Tyj>/Trp53<tm2.1Tyj>
  http://metadb.riken.jp/0011101I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm21TyjTrp53tm21TyjTrp53tm1Tyj
• increased metastatic potential_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0001272I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• increased tumor incidence_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0002020I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• increased squamous cell carcinoma incidence_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0004207I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• increased hemangiosarcoma incidence_Trp53<tm1Tyj>/Trp53<tm1Tyj>
  http://metadb.riken.jp/0003667I129S2SvPasTrp53tm1TyjTrp53tm1TyjTrp53tm1Tyj
• increased metastatic potential_Trp53<tm2.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0001272I129S4SvJaeTrp53tm21TyjTrp53Trp53tm21TyjTrp53
• increased hepatocellular carcinoma incidence_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0003331I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• increased carcinoma incidence_Trp53<tm1Tyj>/Trp53<tm2.1Tyj>
  http://metadb.riken.jp/0002038I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm21TyjTrp53tm21TyjTrp53tm1Tyj
• premature death_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0002083I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• increased tumor incidence_Trp53<tm1Tyj>/Trp53<tm1Tyj>
  http://metadb.riken.jp/0002020I129S2SvPasTrp53tm1TyjTrp53tm1TyjTrp53tm1Tyj
• increased carcinoma incidence_Trp53<tm1Tyj>/Trp53<tm3.1Tyj>
  http://metadb.riken.jp/0002038I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm31TyjTrp53tm31TyjTrp53tm1Tyj
• premature death_Trp53<tm1Tyj>/Trp53<tm1Tyj>
  http://metadb.riken.jp/0002083I129S2SvPasTrp53tm1TyjTrp53tm1TyjTrp53tm1Tyj
• premature death_Trp53<tm1Tyj>/Trp53<+>
  http://metadb.riken.jp/0002083I129S2SvPasTrp53tm1TyjTrp53Trp53Trp53tm1Tyj
• osteopetrosis_Trp53<tm2.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0000067I129S4SvJaeTrp53tm21TyjTrp53Trp53tm21TyjTrp53
• decreased cellular sensitivity to gamma-irradiation_Trp53<tm2.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0003207I129S4SvJaeTrp53tm21TyjTrp53Trp53tm21TyjTrp53
• increased cell proliferation_Trp53<tm3.1Tyj>/Trp53<+>
  http://metadb.riken.jp/0000351I129S4SvJaeTrp53tm31TyjTrp53Trp53Trp53tm31Tyj
• increased tumor incidence_Trp53<tm1Tyj>/Trp53<+>
  http://metadb.riken.jp/0002020I129S2SvPasTrp53tm1TyjTrp53Trp53Trp53tm1Tyj
• increased T cell derived lymphoma incidence_Trp53<tm1Tyj>/Trp53<tm3.1Tyj>
  http://metadb.riken.jp/0002024I129S2SvPas129S4SvJaeTrp53tm1TyjTrp53tm31TyjTrp53tm31TyjTrp53tm1Tyj